Mankind Pharma Limited (MANKIND) — Announcement | 13 August 2026

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Company incorporates wholly owned subsidiary in Netherlands
💡 Investor Takeaway
This establishes a legal entity in Europe, potentially easing future market entry and operational flexibility.

Mankind Pharma announced the incorporation of its wholly owned subsidiary, Mankind Pharma (Netherlands) B.V., in the Netherlands on August 13, 2026, as part of its international expansion strategy to support future growth initiatives.

📄 View Original Announcement (PDF)

About Mankind Pharma Limited (MANKIND)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹97,467.05 Cr P/E: 47.7 ROE: 12.7% ROCE: 13.9% Div Yield: 0.04%

View full MANKIND stock details →

📡 Get AI alerts when MANKIND files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MANKIND — Free

📊 More MANKIND filings

See all MANKIND filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MANKIND files new disclosures

Track MANKIND filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MANKIND — Free

Free account · 2 AI queries/day